Prolyl hydroxylase inhibitors and methods of use
View Patent ↗The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.
1. A compound having the formula:
wherein
R and R 1 are each independently:
i) hydrogen;
ii) substituted or unsubstituted phenyl; or
iii) substituted or unsubstituted heteroaryl;
said substitutions being:
i) C 1 -C 4 linear, branched, or cyclic alkyl;
ii) C 1 -C 4 linear, branched, or cyclic alkoxy;
iii) C 1 -C 4 linear, branched, or cyclic haloalkyl;
iv) halogen;
v) —CN;
vi) —NHC(O)R 4
vii) —C(O)NR 5a R 5b ; or
viii) heteroaryl; or
ix) two substitutions are taken together to form a fused ring having from 5 to 7 atoms;
R 4 is C 1 -C 4 linear, branched, or cyclic alkyl;
R 5a and R 5b are each independently:
i) hydrogen;
ii) C 1 -C 4 linear, branched, or cyclic alkyl; or
iii) R 5a and R 5b are taken together to form a ring having from 3 to 7 atoms;
R 2 is:
i) —OR 6 ; or
ii) —NR 7a R 7b ;
R 6 is hydrogen or C 1 -C 4 linear, branched, or cyclic alkyl;
R 7a and R 7b are each independently:
i) hydrogen; or
ii) C 1 -C 4 linear, branched, or cyclic alkyl; or
iii) R 7a and R 7b are taken together to form a ring having from 3 to 7 ring atoms;
R 3 is hydrogen, methyl, or ethyl;
L is a linking unit having the formula:
—[C(R 8a R 8b )] n —
R 8a and R 8b are each independently hydrogen, methyl, or ethyl;
the index n is from 1 to 3; and
R 9 is hydrogen or methyl;
or a pharmaceutically acceptable salt thereof;
provided R and R 1 are not both hydrogen.
2. A compound according to claim 1 , wherein R is substituted or unsubstituted phenyl.
3. A compound according to claim 1 , wherein R is chosen from 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, and 4-chlorophenyl.
4. A compound according to claim 1 , wherein R is chosen from 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-ethoxyphenyl, 3-ethoxyphenyl, 4-ethoxyphenyl, 2-iso-propoxyphenyl, 3-iso-propoxyphenyl, 4-iso-propoxyphenyl, 2-cyanophenyl, 3-cyanophenyl, and 4-cyanophenyl.
5. A compound according to claim 1 , wherein R 1 is chosen from 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-ethoxyphenyl, 3-ethoxyphenyl, 4-ethoxyphenyl, 2-iso-propoxyphenyl, 3-iso-propoxyphenyl, 4-iso-propoxyphenyl, 2-cyanophenyl, 3-cyanophenyl, and 4-cyanophenyl.
6. A compound according to claim 1 , wherein R is a unit having the formula:
wherein R 10 has the formula —C(O)NR 5a R 5b ; R 5a and R 5b are each hydrogen or R 5a and R 5b are taken together to from a ring having 5 or 6 atoms.
7. A compound according to claim 1 , wherein R 5a and R 5b are taken together to form a pyrrolidin-1-yl ring.
8. A compound according to claim 1 , wherein R is a unit having the formula:
wherein R 10 has the formula —NHC(O)R 4 ; R 4 is a unit chosen from methyl, ethyl, n-propyl, iso-propyl, and cyclopropyl.
9. A compound according to claim 1 , wherein R is a unit having the formula:
wherein R 10 is a heteroaryl unit chosen from 1,2,3,4-tetrazol-5-yl, [1,2,4]triazol-5-yl, imidazol-2-yl, furan-2-yl, furan-3-yl, thiophene-2-yl, and thiophene-3-yl.
10. A compound according to claim 1 , wherein R is substituted or unsubstituted heteroaryl.
11. A compound according to claim 1 , wherein R is a unit chosen from pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, isoquinolin-1-yl, isoquinolin-3-yl, and isoquinolin-4-yl.
12. A compound according to claim 1 , wherein R is a unit chosen from thiazol-2-yl, thiazol-4-yl, 1,2,3,4-tetrazol-5-yl, [1,2,4]triazol-5-yl, imidazol-2-yl, furan-2-yl, furan-3-yl, thiophene-2-yl, and thiophene-3-yl.
13. A compound according to claim 1 , wherein R 2 is —OR 6 ; R 6 is hydrogen or methyl.
14. A compound according to claim 1 , wherein R 6 is hydrogen.
15. A compound according to claim 1 , wherein R 6 is methyl.
16. A compound according to claim 1 , wherein R 2 is —NR 7a R 7b ; R 7a and R 7b are each independently hydrogen, methyl, or ethyl.
17. A compound according to claim 1 , wherein R 2 is chosen from:
i) —NH 2 ;
ii) —NHCH 3 ; or
iii) —N(CH 3 ) 2 .
18. A compound according to claim 1 , wherein R 3 is methyl.
19. A compound according to claim 1 , wherein R 3 is hydrogen.
20. A compound according to claim 1 , wherein L has the formula chosen from:
i) —CH 2 —;
ii) —CH 2 CH 2 —; or
iii) —C(CH 3 ) 2 —.
21. A compound according to claim 1 , wherein L has the formula —CH 2 —.
22. A compound according to claim 1 , having the formula:
wherein R is substituted or unsubstituted phenyl;
said substitutions are chosen from:
i) C 1 -C 4 linear, branched, or cyclic alkyl;
ii) C 1 -C 4 linear, branched, or cyclic alkoxy;
iii) C 1 -C 4 linear, branched, or cyclic haloalkyl;
iv) halogen;
v) —CN;
vi) —NHC(O)R 4
vii) —C(O)NR 5a R 5b ;
viii) heteroaryl; or
ix) two substitutions can be taken together to form a fused ring having from 5 to 7 atoms;
R 4 is C 1 -C 4 linear, branched, or cyclic alkyl;
R 5a and R 5b are each independently:
i) hydrogen;
ii) C 1 -C 4 linear, branched, or cyclic alkyl; or
iii) R 5a and R 5b can be taken together to form a ring having from 3 to 7 atoms.
23. A compound according to claim 1 , having the formula:
wherein R is a heteroaryl unit chosen from thiazol-2-yl, thiazol-4-yl, 1,2,3,4-tetrazol-5-yl, [1,2,4]triazol-5-yl, imidazol-2-yl, furan-2-yl, furan-3-yl, thiophene-2-yl, thiophene-3-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, isoquinolin-1-yl, isoquinolin-3-yl, and isoquinolin-4-yl.
24. A compound according to claim 1 , having the formula:
wherein R is substituted or unsubstituted phenyl;
said substitutions are chosen from:
i) C 1 -C 4 linear, branched, or cyclic alkyl;
ii) C 1 -C 4 linear, branched, or cyclic alkoxy;
iii) C 1 -C 4 linear, branched, or cyclic haloalkyl;
iv) halogen;
v) —CN;
vi) —NHC(O)R 4
vii) —C(O)NR 5a R 5b ;
viii) heteroaryl; or
ix) two substitutions can be taken together to form a fused ring having from 5 to 7 atoms;
R 4 is C 1 -C 4 linear, branched, or cyclic alkyl;
R 5a and R 5b are each independently:
i) hydrogen;
ii) C 1 -C 4 linear, branched, or cyclic alkyl; or
iii) R 5a and R 5b can be taken together to form a ring having from 3 to 7 atoms.
25. A compound according to claim 1 , having the formula:
wherein R is a heteroaryl unit chosen from thiazol-2-yl, thiazol-4-yl, 1,2,3,4-tetrazol-5-yl, [1,2,4]triazol-5-yl, imidazol-2-yl, furan-2-yl, furan-3-yl, thiophene-2-yl, thiophene-3-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, isoquinolin-1-yl, isoquinolin-3-yl, and isoquinolin-4-yl.
26. A compound chosen from:
{[5-(3-Chloro-phenyl)-3-hydroxy-pyridine-2-carbonyl]-amino}-acetic acid methyl ester;
{[5-(4-Chloro-phenyl)-3-hydroxy-pyridine-2-carbonyl]-amino}-acetic acid methyl ester;
{[5-(2-Chloro-phenyl)-3-hydroxy-pyridine-2-carbonyl]-amino}-acetic acid methyl ester;
{[5-(4-Fluoro-phenyl)-3-hydroxy-pyridine-2-carbonyl]-amino}-acetic acid methyl ester;
[(3-Hydroxy-5-(4-methylphenyl)-pyridine-2-carbonyl)-amino]-acetic acid methyl ester;
{[3-Hydroxy-5-(4-isopropyl-phenyl)-pyridine-2-carbonyl]-amino}-acetic acid methyl ester;
{[5-(4-Ethyl-phenyl)-3-hydroxy-pyridine-2-carbonyl]-amino}-acetic acid methyl ester;
{[3-Hydroxy-5-(3-trifluoromethyl-phenyl)-pyridine-2-carbonyl]-amino}-acetic acid methyl ester;
{[5-(4-Cyano-phenyl)-3-hydroxy-pyridine-2-carbonyl]-amino}-acetic acid methyl ester;
{[5-(3-Cyano-phenyl)-3-hydroxy-pyridine-2-carbonyl]-amino}-acetic acid methyl ester;
{[5-(3-Carbamoyl-phenyl)-3-hydroxy-pyridine-2-carbonyl]-amino}-acetic acid methyl ester;
({3-Hydroxy-5-[3-(pyrrolidine-1-carbonyl)-phenyl]-pyridine-2-carbonyl}-amino)-acetic acid methyl ester;
({5-[3-(Cyclopropanecarbonyl-amino)-phenyl]-3-hydroxy-pyridine-2-carbonyl}-amino)-acetic acid methyl ester;
({3-Hydroxy-5-[3-(2H-tetrazol-5-yl)-phenyl]-pyridine-2-carbonyl}-amino)-acetic acid methyl ester;
[(5-Hydroxy-[3,3′]bipyridinyl-6-carbonyl)-amino]-acetic acid methyl ester
[(5′-Hydroxy-[2,3′]bipyridinyl-6′-carbonyl)-amino]-acetic acid methyl ester;
[(3-Hydroxy-5-pyrimidin-5-yl-pyridine-2-carbonyl)-amino]-acetic acid methyl ester;
[(3-Hydroxy-5-isoquinolin-4-yl-pyridine-2-carbonyl)-amino]-acetic acid methyl ester;
[(3-Hydroxy-5-thiazol-2-yl-pyridine-2-carbonyl)-amino]-acetic acid methyl ester;
{[5-(3-Chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}-acetic acid;
{[5-(4-Chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}-acetic acid;
{[5-(2-Chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}-acetic acid;
{[5-(4-Fluorophenyl)-3-hydroxypyridine-2-carbonyl]amino}-acetic acid;
[(3-Hydroxy-5-(4-methylphenyl)pyridine-2-carbonyl)amino]-acetic acid;
{[5-(4-Ethylphenyl)-3-hydroxypyridine-2-carbonyl]amino}-acetic acid;
{[3-Hydroxy-5-(4-isopropylphenyl)pyridine-2-carbonyl]amino}-acetic acid;
{[3-Hydroxy-5-(3-trifluoromethylphenyl)pyridine-2-carbonyl]amino}-acetic acid;
{[5-(4-Cyanophenyl)-3-hydroxypyridine-2-carbonyl]amino}-acetic acid;
{[5-(3-Cyanophenyl)-3-hydroxypyridine-2-carbonyl]amino}-acetic acid;
{[5-(5-Chloro-2-methylphenyl)-3-hydroxypyridine-2-carbonyl]amino}-acetic acid;
{[3-Hydroxy-5-(4-isopropoxyphenyl)pyridine-2-carbonyl]amino}-acetic acid;
({5-[3-(Cyclopropanecarbonylamino)phenyl]-3-hydroxy-pyridine-2-carbonyl}-amino)-acetic acid;
({3-Hydroxy-5-[3-(pyrrolidine-1-carbonyl)phenyl]-pyridine-2-carbonyl}amino)-acetic acid;
({3-Hydroxy-5-[3-(2H-tetrazol-5-yl)phenyl]-pyridine-2-carbonyl}-amino)-acetic acid;
[(5′-Hydroxy-[2,3′]bipyridinyl-6′-carbonyl)-amino]-acetic acid;
[(5-Hydroxy-[3,3′]bipyridinyl-6-carbonyl)-amino]-acetic acid;
[(3-Hydroxy-5-pyrimidin-5-yl-pyridine-2-carbonyl)-amino]-acetic acid;
[(3-Hydroxy-5-isoquinolin-4-yl-pyridine-2-carbonyl)-amino]-acetic acid;
[(3-Hydroxy-5-thiazol-2-yl-pyridine-2-carbonyl)-amino]-acetic acid;
{[5-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-3-hydroxy-pyridine-2-carbonyl]-amino}-acetic acid;
5-(Chlorophenyl)-N-(2-amino-2-oxo-1,1-dimethylethyl)-3-hydroxylpyridin-2-yl amide;
5-(Chlorophenyl)-N-(2-amino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;
5-(Chlorophenyl)-N-(2-amino-2-oxo-1-methylethyl)-3-hydroxylpyridin-2-yl amide;
5-(4-Methylphenyl)-N-(2-methylamino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;
5-(3-Chlorophenyl)-N-(2-methylamino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;
2-{[5-(3-Chloro-phenyl)-3-hydroxy-pyridine-2-carbonyl]-amino}-2-methyl-propionic acid methyl ester;
2-{[5-(3-Chlorophenyl)-3-hydroxy-pyridine-2-carbonyl]-amino}-2-methyl-propionic acid
3-[(3-Hydroxy-5-(4-methylphenyl)-pyridine-2-carbonyl)-amino]-propionic acid ethyl ester;
3-[(3-Hydroxy-5-(3-chlorophenyl)-pyridine-2-carbonyl)-amino]-propionic acid ethyl ester;
3-{[5-(3-Chlorophenyl)-3-hydroxy-pyridine-2-carbonyl]-amino}-propionic acid;
3-[(3-Hydroxy-5-(4-methylphenyl)-pyridine-2-carbonyl)-amino]-propionic acid;
5-(Chlorophenyl)-N-(3-amino-3-oxo-1,1-dimethylpropyl)-3-hydroxylpyridin-2-yl amide; and
5-(3-Chlorophenyl)-N-(2-dimethylamino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide; or
a pharmaceutically acceptable salt thereof.
27. A composition comprising:
A) one or more compounds according to claim 1 ; and
B) one or more excipients or carriers.
28. A compound according to claim 1 , wherein the compound is a pharmaceutically acceptable salt of either basic groups or acid groups.
29. A compound according to claim 1 , wherein the compounds are salts comprising anions chosen from chloride, bromide, iodide, sulfate, bisulfate, carbonate, bicarbonate, phosphate, formate, acetate, propionate, butyrate, pyruvate, lactate, oxalate, malonate, maleate, succinate, tartrate, fumarate, and citrate.
30. A compound according to claim 1 , wherein the compounds are salts comprising cations chosen from sodium, lithium, potassium, calcium, magnesium, and bismuth.
31. A compound according to claim 1 , having the formula:
wherein R is substituted or unsubstituted phenyl;
said substitutions are chosen from:
i) C 1 -C 4 linear, branched, or cyclic alkyl;
ii) C 1 -C 4 linear, branched, or cyclic alkoxy;
iii) C 1 -C 4 linear, branched, or cyclic haloalkyl;
iv) halogen;
v) —CN;
vi) —NHC(O)R 4
vii) —C(O)NR 5a R 5b ;
viii) heteroaryl; or
ix) two substitutions can be taken together to form a fused ring having from 5 to 7 atoms;
R 4 is C 1 -C 4 linear, branched, or cyclic alkyl;
R 5a and R 5b are each independently:
i) hydrogen;
ii) C 1 -C 4 linear, branched, or cyclic alkyl; or
iii) R 5a and R 5b can be taken together to form a ring having from 3 to 7 atoms.
32. A compound according to claim 1 , having the formula:
wherein R is a heteroaryl unit chosen from thiazol-2-yl, thiazol-4-yl, 1,2,3,4-tetrazol-5-yl, [1,2,4]triazol-5-yl, imidazol-2-yl, furan-2-yl, furan-3-yl, thiophene-2-yl, thiophene-3-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, isoquinolin-1-yl, isoquinolin-3-yl, and isoquinolin-4-yl.